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Background. Glioblastoma (GBM) genomes feature re-
current genetic alterations that dysregulate core intracel-
lular signaling pathways, including the G1/S cell cycle
checkpoint and the MAPK and PI3K effector arms of re-
ceptor tyrosine kinase (RTK) signaling. Elucidation of
the phenotypic consequences of activated RTK effectors
is required for the design of effective therapeutic and diag-
nostic strategies.
Methods. Geneticallydefined,G1/Scheckpoint-defective
cortical murine astrocytes with constitutively active Kras
and/or Pten deletion mutations were used to systemati-
cally investigate the individual and combined roles of
these 2 RTK signaling effectors in phenotypic hallmarks
of glioblastoma pathogenesis, including growth, migra-
tion, and invasion in vitro. A novel syngeneic orthotopic
allograft model system was used to examine in vivo
tumorigenesis.
Results. Constitutively active Kras and/or Pten deletion
mutations activated both MAPK and PI3K signaling.
Their combination led to maximal growth, migration,
and invasion of G1/S-defective astrocytes in vitro and
produced progenitor-like transcriptomal profiles that
mimic human proneural GBM. Activation of both RTK
effector arms was required for in vivo tumorigenesis and
produced highly invasive, proneural-like GBM.
Conclusions. These results suggest that cortical astrocytes
can be transformed into GBM and that combined dysregu-
lation of MAPK and PI3K signaling revert G1/S-defective
astrocytes to a primitive gene expression state. This
genetically-defined, immunocompetent model of proneu-
ral GBM will be useful for preclinical development of
MAPK/PI3K-targeted, subtype-specific therapies.
Keywords: astrocytes, genetically engineered mouse,
glioblastoma, invasion, Pten.
G
lioblastomas (GBM; World Health Organization
[WHO] grade IV) account for .85% of astrocy-
tomas and are uniformly lethal.1 Their diffuse in-
filtration of normal brain makes complete surgical
resection impossible, and further eradicating tumor cells
with radiation or chemotherapy remains difficult. Thus,
recurrence is almost certain, occurring in at least 90%
of cases near the resection site.2,3 This sobering clinical
reality has fueled investigation of the biological mecha-
nisms responsible for GBM migration and invasion, par-
ticularly the intracellular signaling pathways that govern
thesephenotypes.TheCancerGenome Atlas (TCGA)cat-
alogued oncogenic mutations and copy number alter-
ations in GBM and showed that these abnormalities
occur primarily in genes of 3 core intracellular pathways,
namely the RB-regulated G1/S cell cycle checkpoint,
receptor tyrosine kinase (RTK) signaling, and TP53.
Approximately 74% of human GBM harbored events in
all 3 pathways, whereas ,5% harbored events in only
one of the three.4 In contrast, over 90% contained
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mutations in both RB and RTK pathway genes (http://
tcga-data.nci.nih.gov/tcga/).
RTK and their downstream effectors, RAS/MAPK
andPI3K/AKT/mTOR,have receivedparticular interest,
because kinases within these pathways represent poten-
tial targets for therapeutic intervention.5 RTK pathway
kinases encoded by the EGFR, ERBB2, PDGFRA,
MET, KRAS, PIK3CA, and AKT1 genes are frequently
amplified or mutationally activated, whereas negative
regulators of RAS and PI3K signaling, NF1 and PTEN,
are frequentlydeletedormutationally inactivated, respec-
tively.4 On the basis of these genetic alterations, 88% of
GBM are predicted to harbor activated RTK signaling
through these 2 effector arms, and virtually all show
RAS activation.6,7
However, clinical trial results with RTK-targeted ther-
apeutics, particularly EGFR tyrosine kinase inhibitors
(TKI), have been disappointing.8 EGFR is amplified or
mutated in 36%–45% of GBM,4,9 but only a small per-
centage of these tumors respond to EGFR TKI. GBM
exhibit both inter- and intratumoral genetic heterogenei-
ty, and both neighboring and individual tumor cells can
harbor amplifications in .1 distinct RTK gene.10 A
recentmouse model studyshowed thatMet may function-
ally compensate for EGFR signaling after EGFR
TKI-mediated inhibition, suggesting one potential resis-
tance mechanism particularly in the subset of GBM
with EGFR and MET coamplification.11 In addition,
coexpression of the constitutively active EGFRvIII extra-
cellular domain truncation mutant and PTEN correlated
with EGFR TKI response. In contrast, loss of PTEN ex-
pressionwasassociatedwith treatment failure, suggesting
that uncoupling of PI3K signaling from EGFR may be an
additional EGFR TKI resistance mechanism.12
Since its discovery .10 years ago, the PTEN tumor
suppressor gene has been extensively investigated. The em-
bryonic lethalityobserved inPten-null miceunderscores its
importance during development.13,14 PTEN is also critical
in many cellular functions relevant to tumorigenesis, in-
cluding proliferation, survival, migration, and invasion.15
Inactivating PTEN mutations or deletions are present in
30%–40% of human GBM, and TCGA identified it
as the second most commonly mutated GBM gene.4,16
A more complete understanding of the combinatorial
roles of RTK signaling through RAS and PI3K effectors
in GBM pathogenesis, particularly the migratory and
invasive phenotypes that make treatment difficult, is
therefore required to develop more effective, targeted
therapies.3
To overcome this limitation, we have generated
primary astrocytes from a series of conditional, genetical-
ly engineered mouse (GEM) models, in which 2 of the 3
core GBM pathways were genetically targeted, either
alone or in combination, all on a common C57Bl/
6-based genetic background. After Cre-mediated recom-
bination, these mice express an N-terminal 121-amino
acid truncation mutant of SV40 large T antigen (T121,
hereafter called T) from the human glial fibrillary acidic
protein (GFAP) promoter,17 which inactivates all 3 Rb
family proteins—Rb, p107, and p130—and ablates the
G1/S cell cycle checkpoint.18 In addition, these mice
have a constitutively active KrasG12D mutant (R)19 and/
or either heterozygous or homozygous Pten deletion
(P+/2 or P2/2).20 Our previous studies have shown that
particular combinations of these 3 alleles recapitulate
the histopathological progression from low-grade
(WHO grade II, A2) to high-grade astrocytomas (WHO
grade III and IV, A3 and GBM, respectively) after recom-
bination in adult GFAP+ mouse brain cells.20 Therefore,
we hypothesized that these primary GEM astrocytes
would provide a unique opportunity to dissect the indi-
vidual and combinatorial roles of activated MAPK and
PI3K signaling in biological processes relevant to GBM
pathogenesis, including cellular growth (proliferation




Heterozygous TgGZT121 mice were maintained on a
BDF1 background.17 Heterozygous KrasG12D condition-
al knock-in and PtenloxP/loxP mice were maintained on a
C57/Bl6 background.19,21 All experimental animals
were .94% C57/Bl6. PCR genotyping was performed
as previously described.17,19,21 Animal studies were ap-
proved by the University of North Carolina Institutional
Animal Care and Use Committee.
Primary Astrocyte Cultures
Primary astrocytes were cultured as previously de-
scribed.17 In brief, cells were selectively harvested from
the cortices of postnatal day 1–4 pups, manually dissoci-
ated by trituration in trypsin, and incubated at 378C for
20 min. Cells were pelleted, resuspended, and cultured
in DMEM supplemented with 10% fetal bovine serum
and 1% penicillin–streptomycin (complete media). At
50% confluence, cells were infected at a multiplicity of in-
fection of 50 for 6 h in complete media with a recombi-
nant adenoviral vector expressing Cre recombinase
from the constitutive cytomegalovirus promoter
(Ad5CMVCre, University of Iowa Gene Transfer Vector
Core).22 After infection, cells were rinsed in phosphate-
buffered saline and cultured in complete media at 378C
in 5% CO2. All immunoblot, cell growth, apoptosis,
wound closure, collagen invasion, time-lapse microsco-
py, microarray, and orthotopic allograft experiments
were performed with genotype-confirmed primary astro-
cytes, under passage 10 post-Ad5CMVCre infection, in
log phase growth, and cultured in complete media
unless otherwise stated.
Microarray Analyses
All original microarray data are publically available at
the UNC Microarray Database (http://genome.unc.edu)
and Gene Expression Omnibus, accession number
GSE40265.
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Orthotopic Allografts
Adult wild-type C57Bl/6 mice ( ≥ 3 months of age) were
anesthetized with Avertin (250 mg/kg) and placed in a
stereotactic frame (Kopf, Tujunga, CA). After a 0.5-cm
scalp incision, 105 cells in 5 mL of 5% methylcellulose
were injected into the right basal ganglia using coordi-
nates 1, -2, and -4 mm (A, L, D) from the Bregma suture
as previously described.23
Statistics
Apoptosis, viability, and time-lapse microscopy data
were analyzed using 1-way ANOVA with Tukey’s multi-
ple comparisons correction in GraphPad Prism 5
(GraphPad, San Diego, CA). Wound closure data were
analyzed using pairwise Student’s t tests. Doubling
times from cell growth assays were compared using
1-way ANOVA with Tukey’s correction in Stata,
version 10 (College Station, TX). Multiple linear regres-
sion, Kaplan–Meier plots, and log-rank analyses were
conducted in Stata. All comparisons were significant at
a ¼ 0.05.
Supplement
Supplemental methods, figures, tables, and videos can be
found online.
Results
PI3K and MAPK Signaling and Growth of G1/S
Checkpoint-Defective Primary Astrocytes
To determine how targeted genetic disruption of Rb, Ras,
and PI3K signaling affects tumorigenesis, we isolated and
culturedprimary cortical astrocytes fromnewbornmouse
pups with the following genotypes: T, TR, TPwt/loxP,
TPloxP/loxP, TRPwt/loxP, and TRPloxP/loxP. After infection
with Ad5CMVCre to induce recombination, we per-
formed a series of in vitro experiments to probe how
these genetic events affect PI3K and Ras/MAPK signal-
ing, proliferation, apoptosis, migration, invasion, and
gene expression.
The Rb familyof G1/Scell cycle checkpoint regulatory
proteins Rb1, p107, and p130 are encoded in mice by
Rb1, Rbl1, and Rbl2. Deletion of all 3 Rb family genes
in mouse embryonic fibroblasts disrupts this checkpoint
and enhances cell cycle entry.18 We confirmed that
T-mediated inactivation of all 3 Rb family proteins dis-
rupted the G1/S checkpoint because T but not wild-type
astrocytes continued to enter S phase and proliferate after
serum starvation in media with 0.5% serum (data not
shown). Under normal growth conditions, T astrocytes
showedessentiallynoactivationofthePI3Kpathwayeffec-
tors Akt and S6 (Fig. 1A). Moreover, p-Akt and p-S6 levels
were similar to wild-type astrocytes (Supplementary Fig.
S1A). These results demonstrate that a defective G1/S
checkpoint alone does not activate PI3K signaling
(Fig. 1A). Pten deletion (TP+/2 and TP2/2) increased
PI3K pathway activation, because p-Akt and p-S6 levels
in TP2/2 .. TP+/2 .T astrocytes. Kras activation
(TR and TRP+/2) further increased Akt and S6 phosphor-
ylation. Akt and S6 phosphoprotein levels in at least 2 of 3
TR and TRP+/2 isolates were similar to astrocytes
completely lacking Pten (TP2/2 and TRP2/2). These
results indicate that activated Kras, biallelic Pten deletion,
or their combination potentiates PI3K pathway signaling
in G1/S-defective astrocytes.
We also measured MAPK pathway activation. In at
least 2 of 3 isolates per genotype, p-Mek1/2 levels were
TRP2/2 . TRP+/2 . TP2/2 . TR ≥ TP+/2 ≥ T ≥
wild-type astrocytes (Fig. 1A and Supplementary
Fig. S1A). These data suggest that Kras activation (TR)
or Pten deletion (TP+/2, TP2/2) alone induce increased
MAPK signaling, which is augmented when these muta-
tions are combined (TRP+/2, TRP2/2). Maximum sig-
naling in TRP2/2astrocytes highlights the combinatorial
effects of these mutations on the 2 main RTK effector
pathways.
To determine how Rb, Ras, and/or PI3K pathway al-
terations affected cellular growth, cultured astrocytes
from all 6 genotype combinations were counted over 7
days and apoptosis was quantified. Wild-type astrocyte
numbers were essentially unchanged throughout the
timecourseexamined (Fig.1B).Tastrocytes showedan in-
creased growth rate (5.7 day doubling time) (Fig. 1B and
C) and 2-fold increased apoptosis (Supplementary Fig.
S1B) relative to wild-type astrocytes. Similar results were
observed in T-driven astrocytomas in vivo.17 TP+/2 and
TP2/2 astrocytes grew faster (doubling times 4.1 and
3.4 days), and apoptosis in TP2/2 was lower than T astro-
cytes (P , .05). Kras activation alone (TR) or in combi-
nation with Pten deletion (TRP+/2, TRP2/2) increased
growth because TR, TRP+/2, and TRP2/2 astrocytes
displayed the shortest doubling times of 3.8, 3.4, and 2.0
days, respectively (Fig. 1C). Apoptosis levels in TR were
lower than T (P , .05) but similar to TP2/2 astrocytes
(P . .05) (Fig. 1D and Supplementary Fig. S2), suggesting
that the increased growth in TP2/2 versus TR astrocytes is
attributable to a higher proliferation rate in the former.
Apoptosis in TRP2/2 astrocytes was lower than both
TP2/2 and TR (P , .001 and P ¼ .08, respectively)
(Fig. 1D and Supplementary Fig. S2). Overall, these data
suggest that activated Kras or Pten loss mitigate the apo-
ptosis induced by T-mediated ablation of the G1/S check-
point in cultured murine astrocytes. Moreover, the
proliferative and anti-apoptotic effects of T, R, and P com-
bined (TRP2/2) produced the largest net positive effect on
cellular growth.
Both Kras Activation and Pten Loss Contribute
to G1/S-Defective Astrocyte Migration In Vitro
We have previously shownthat TR,TRP+/2, andTRP2/2
mice frequently develop high-grade astrocytomas (HGA),
including GBM, whereas T, TP+/2, and TP2/2 mice
develop low-grade astrocytomas (LGA) that infrequently
progress to HGA.20 Therefore, we hypothesized that G1/
S-defective astrocytes with activated Kras and/or Pten
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deletion would display enhanced migration in vitro. To
address these hypotheses, we evaluated migration using 2
different assays.
Wound closure, or “scratch,” assays have been exten-
sively used to examine the molecular mechanisms of mi-
gration.24 We used this assay to quantify astrocyte
migrationafter24 h.ActivatedKras, aloneor incombina-
tion with Pten loss, significantly increased migration
(Fig. 2A and B) because 2.8-, 2.8-, and 1.9-fold increases
in wound closure were evident in TR vs. T, TRP+/2 vs.
TP+/2, and TRP2/2 vs. TP2/2 astrocytes (P ≤ .0005).
Monoallelic Pten deletion did not significantly affect mi-
gration of G1/S-defective astrocytes with (TR) and
without (T) concomitant Kras activation (TRP+/2 vs.
TR, P ¼ .5; TP+/2 vs. T, P ¼ .6). In contrast, biallelic
Pten deletion increased migration by 2.7-fold in TP2/2
compared with T astrocytes (P ¼ .009), and migration
nearly doubled (by 1.8-fold) in TRP2/2 compared with
TR astrocytes (P , .0001). These results show that
either Kras activation alone or biallelic Pten deletion,
with or without activated Kras, increased G1/
S-defective astrocyte migration, and all 3 alterations re-
sulted in maximal migration.
Because wound closure can be achieved through a
combination of cell migration, spreading, proliferation,
and interaction with neighboring cells, we examined the
cell autonomous genetic contributions to migration by
tracking cellular movement over 1 h with use of time-
lapse video microscopy and calculating the velocities of
individual cells (Fig. 2C and videos SV1–4). Wild-type
astrocytes were relatively nonmotile. G1/S checkpoint
disruption alone (T) increased mean cellular velocity by
4.3-fold compared with wild-type astrocytes. Activated
Kras (TR) or Pten deletion (TP+/2, TP2/2) only slightly
increased migration of G1/S-defective T astrocytes. TR,
TRP+/2, and TRP2/2 astrocytes migrated faster than
their counterparts without activated Kras. Combining
all 3 alterations in TRP2/2 astrocytes resulted in
maximal migration with a mean velocity of 47+2 mm/
h. Of note, genotype significantly influenced mean veloc-
ity (1-way ANOVA, P , .0001), and all pairwise geno-
type comparisons were significant (P , .05) except T vs.
TP2/2. Multivariable regression analysis confirmed the
independent contribution of all 3 alleles (P , .001).
Taken together, these results showed that Kras activation
and/or Pten loss increased G1/S-defective astrocyte mi-
gration and that all 3 alterations resulted in maximal mi-
gration in both multicellular (Fig. 2B) and individual cell
(Fig. 2C) contexts.
Weconfirmed the effects of activated Ras andPI3K sig-
naling on migration by examining wound closure in
TRP2/2 astrocytes after pharmacological inhibition of
mTOR, PI3K, and MEK with rapamycin, LY294002,
and U0126, respectively (Fig. 2D). S6 phosphorylation
was virtually eliminated by rapamycin and LY294002
(Supplementary Fig. S6) and decreased wound closure
by 22% and 45% (P ≤ .0004). U0126 inhibited Erk
phosphorylation (Supplementary Fig. S3A) and de-
creased wound closure by 35% (P , .001). In contrast,
combined inhibition of PI3K and MEK with LY294002
Fig. 1. MAPK and PI3K signaling and growth of G1/S-defective astrocytes with activated Kras and/or Pten deletion. Representative
immunoblots showing MAPK and PI3K pathway signaling in G1/S-defective astrocytes with activated Kras, Pten deletion, or both (A).
Growth of G1/S defective astrocytes in vitro. Cell number was assessed by counting cells at days 1–7 (B). Mean doubling times+95%
confidence intervals were calculated from the exponential growth curves in B (C). Growth rates were significantly different across genotypes
(P , .0001). Apoptosis in G1/S defective astrocytes in vitro (D). Colors compare genotypes with and without activated Kras. Error bars
represent standard error (SEM).
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and U0126 decreased TRP2/2 astrocyte wound closure
by 85%, relative to untreated TRP2/2 astrocytes
(P , .0001). Moreover, combined LY294002/U0126
treatment decreased TRP2/2 astrocyte migration to
similar levels as T astrocytes without activated Kras and
deleted Pten (Fig. 2B) and minimally affected viability at
24 h(datanot shown)or5days (Supplementary Fig. S3B).
Pten Loss Is Necessary for G1/S-Defective Astrocyte
Invasion In Vitro
Astrocytomas are characterized by their ability to invade
the surrounding brain parenchyma. We used our astro-
cyte panel to ascertain which core signaling pathway al-
terations were necessary for collagen invasion in vitro.25
T astrocytes showed minimal invasion over 7 days
(Fig. 3A and B). Invasion was only 40% higher in TR as-
trocytes (P ¼ .6), suggesting that Kras activation alone
was insufficient for invasion. However, a Kras effect
was evident when combined with monoallelic Pten
deletion because TRP+/2 showed 19-fold increased
invasion compared with TP+/2 astrocytes (P ¼ .01). In
contrast, a Kras-specific effect was not apparent when
combined with biallelic Pten deletion because TRP2/2
showed only a 40% increase in invasion compared with
TP2/2 astrocytes (P ¼ .2). Although monoallelic Pten
deletion (TP+/2) produced a moderate (6-fold), statisti-
cally insignificant increase in invasion (P ¼ .09), biallelic
Pten deletion (TP2/2) increased invasion by 68-fold
comparedwith Tastrocytes (P , .0001,Fig. 3B), suggest-
ing that Pten loss alone is sufficient to induce G1/
S-defective astrocyte invasion. Deletion of one
(TRP+/2) or both (TRP2/2) Pten allele(s) increased
invasion by 85- (P ¼ .01) and 69-fold (P ¼ .001) over
G1/S-defective astrocytes with activated Kras (TR).
Thus, although the invasion-related effects of Kras activa-
tion were evident in G1/S-defective astrocytes with het-
erozygous, but not homozygous, Pten deletion, Pten
loss-mediated invasion was independent of Kras
activation.
In addition to proliferation and migration, genetic ac-
tivation of Kras and Pten deletion maximally increased
G1/S-defective astrocyte invasion in vitro (TRP2/2).
Therefore, we next confirmed the invasion-related
effects of activated PI3K and MEK signaling by examin-
ing TRP2/2 astrocyte invasion after pharmacological in-
hibition of mTOR, PI3K, and MEK. Whereas rapamycin,
LY294002, and U0126 inhibited TRP2/2 astrocyte inva-
sion by 47%, 33%, and 49% (P . .05), combined treat-
ment with LY294002/U0126 significantly decreased
invasion by 90% (P ¼ .01) (Fig. 3C). Of note, all
drug treatments minimally affected viability at 5 days
(P . .05) (Supplementary Fig. S3B).
Pten Restoration Reduces Proliferation, Migration,
and Invasion
The data above suggest that PI3K pathway activation
induced by Pten loss is critical for G1/S-defective astro-
cyte proliferation, migration, and invasion. To confirm
its role in these processes, we restored Pten expression
by infecting TRP2/2 astrocytes with a retrovirus encod-
ing wild-type murine Pten. Pten expression was evident
in 60% of cells within 48 h of infection and attenuated
downstream PI3K signaling at p-Akt (56%–73%) and
p-S6 (68%–85%). In contrast, Pten restoration did not
Fig. 2. Kras activation and Pten loss increase G1/S-defective astrocyte migration. Representative photomicrographs of wound closure in T,
TR, and TRP2/2 astrocytes at 0 and 24 h (A). Mean percent wound closure+SEM at 24 h (B). Colors compare genotypes with and without
activated Kras. Mean velocity+SEM of individual astrocytes measured using time-lapse microscopy for 1 h (C). Colors compare genotypes
with and without activated Kras. Wound closure of TRP2/2 astrocytes treated with 10 nM rapamycin (Rapa), 50 mM LY294002 (LY), 10 mM
U0126, or both LY294002 and U0126 (D). Mean percent wound closure+SEM is shown relative to untreated (No Drug) TRP2/2 astrocytes.
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significantly alter MAPK signaling of p-Mek and p-Erk
(Fig. 4A).
Restoring Pten increased TRP2/2 astrocyte doubling
time from 1.8 to 2.7–3.4 days (Fig. 4B and C), growth
rates similar to TR astrocytes without Pten deletion
(Fig. 1B). Pten also significantly reduced, but did not
completely prevent, migration in the wound closure
assay (P ≤ .0002) (Fig. 4D). GFP transfection did not sig-
nificantly alter migration (Fig. 4D) compared with
untransfected TRP2/2 astrocytes (Fig. 2B) (P ¼ .1).
These data are consistent with wound closure (Fig. 2B)
and time-lapse microscopy (Fig. 2C) experiments using
TR astrocytes and confirm the Kras contribution to mi-
gration. Similarly, invasion was significantly decreased
but not prevented in Pten-rescued TRP2/2 astrocytes;
instead, rescued TRP2/2 cells showed 58% and 32% re-
duction in invasion compared with control GFP-infected
TRP2/2 cells at 3 and 5 days, respectively (P ≤ .0003)
(Fig. 4E). These data are consistent with data in Fig. 3C,
in which TRP2/2 invasion was only partially mitigated
after pharmacologically inhibiting PI3K or mTOR.
To confirm the Kras-independent effects of Pten on
migration, we restored Pten in cells without activated
Kras (TP2/2). Wound closure was reduced to 7.6%
(SupplementaryFig.S4), levelscomparable tothose inTas-
trocytes. This demonstrated that Pten loss significantly
contributed to migration in the absence of Kras activation.
Activated MAPK and PI3K Signaling in G1/S-Defective
Astrocytes Produces Gene Expression Profiles Similar to
Human Proneural HGA
Results above demonstrate that the phenotypic effects of
Kras activation and Pten loss are contextual and comple-
mentary. Next, we determined their effects on genome-
wide transcriptome patterns using microarrays. These
experiments showed that cultured G1/S-defective
astrocytes display distinct expression profiles depending
on the presence of activated Kras, Pten loss, or both.
Consensus clustering of 23 samples identified 4 classes
with high confidence (Supplementary Fig. S5); 3 of these
classes (22 samples) were used in subsequent analyses
(see Supplemental Methods). Although different isolates
from identical genotypes were sometimes present in
different clusters, Class 1 contained only T and TP astro-
cytes, Class 2 contained all analyzed TR astrocytes, and
Class 3 contained only TRP astrocytes (Fig. 5A).
Compared with Class 1 and 2, Class 3 (green bar) astro-
cyte transcriptomes were significantly enriched for
migration, invasion, and stem cell signatures (Fig. 5B,
Supplementary Table S1). These data are consistent
with the above results demonstrating maximal migration
and invasion in TRP astrocytes and suggest that these
astrocytes may be stem-like and capable of initiating
tumorigenesis.
Fig. 3. Pten deletion is necessary for maximum G1/S-defective astrocyte invasion. Representative photomicrographs of collagen invasion of T,
TR, and TRP2/2 astrocytes at 4 days (A). Mean percent invasion+SEM into collagen after 4 days (B). Colors compare genotypes with and
without activated Kras. Collagen invasion of TRP2/2 astrocytes treated with 10 nM rapamycin (Rapa), 50 mM LY294002 (LY), 10 mM
U0126, or both LY294002 and U0126 (C). Mean percent invasion+SEM is shown relative to untreated (No Drug) TRP2/2 astrocytes.
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Fig. 4. Restoration of Pten expression limits growth, migration, and invasion in TRP2/2 astrocytes. Representative immunoblot of MAPK and
PI3K pathway signaling in TRP2/2 astrocytes after infection with retrovirus containing Pten or GFP cDNA (A). Growth (B), doubling time (C),
mean percent wound closure at 24 h (D), and mean percent invasion into collagen at 1, 3, and 5 days (E) of Pten rescued versus nonrescued
(GFP) TRP2/2 astrocytes. Mean doubling times+95% confidence intervals in C were calculated from the exponential growth curves in
B. All experiments are the mean of at least three independent experiments using different astrocyte isolations. Error bars are SEM.
Fig. 5. Gene expression profiling of G1/S-defective astrocytes with activated Kras and/or Pten deletion. Consensus clustering of 22
independently isolated astrocyte cultures identifies 3 clusters (A). Individual isolates are repeated on the X and Y axes. Darker shades of blue
signify isolates that cluster together most often. Single sample GSEA (ssGSEA) of the 15 most significantly enriched gene signatures from
MsigDB in Class 3 (green) astrocytes (B). ssGSEA of human GBM signatures (C). ssGSEA of murine neural lineage signatures (D). Red signifies
higher enrichment scores of signature genes.
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Next, we examined whether these astrocytes were en-
riched for TCGA human GBM26 and Phillips prognostic
HGA27 subtype signatures using gene set analysis (GSA)
(Supplementary Table S2) and single sample gene set en-
richment analysis (ssGSEA) (Fig. 5C). Class 3 TRP astro-
cytes were highly enriched for TCGA proneural and
neural signatures (P ≤ .003) and showed particularly
low expression of the TCGA (P ¼ .09) and Philips
(P ¼ .04) mesenchymal subtype signatures. Individual
Class 3 astrocytes were also enriched for Phillips proneu-
ral and proliferative signatures, but the entire group was
not significantly associated with them (P ≥ .1). None of
the HGA signatures were significantly enriched in Class
1 T/TP or Class 2 TR astrocytes, but several samples in
these classes expressed low levels of proneural and
neural signatures, further highlighting their dissimilarity
to Class 3 TRP astrocytes.
Wethen investigatedexpressionofadultmurineneural
cell lineage-specific signatures.28 Class 3 TRP astrocytes
showed high expression of oligodendrocyte progenitor
(OPC)-specific genes and low expression of cultured
astrocytes-specific genes (Fig. 5D, Supplementary Table
S2), suggesting that the combination of Kras activation
and Pten loss induces a more primitive expression
pattern in G1/S-defective astrocytes. In contrast, Class
1 (T, TP) astrocytes showed low expression of OPC signa-
ture genes but instead expressed cultured astrocyte-
specific genes.
A PI3K Activation Signature Is Enriched in Human
Proneural GBM
Because PI3K signaling activation caused by Pten loss was
critical for proliferation, migration, and invasion of G1/
S-defective TRP2/2 astrocytes, we next defined gene sig-
natures specific to activated PI3K signaling. First, PI3K
signaling was pharmacologically inhibited in TRP2/2 as-
trocytes using the dual PI3K/mTOR inhibitor PI-103, the
PI3K inhibitor LY294002, and the mTOR inhibitor rapa-
mycin. Each drug maximally inhibited Akt-mediated S6
phosphorylation within 2–4 h of treatment, and
maximal inhibition lasted at least 24 h, except LY2940
02, which lasted 4 h (Supplementary Fig. S6A–D). To
identify PI3K pathway signatures, we analyzed mRNA
expression of drug-treated samples after 4 h of inhibition
(inhibited) and 4, 8, and 24 h after release from inhibition
(released). We used large average submatrices (LAS), an
unsupervised significance-based biclustering method, to
identify groups of coordinately expressed genes.29
The top 5 biclusters, in order of decreasing statistical
significance, consistedof genes highly expressed in the fol-
lowing contexts (data not shown): (i) all times after
LY294002 release; (ii) all inhibited samples, regardless
of the specific drug; (iii) 24 h after release from inhibition,
regardless of the drug; (iv) all times after rapamycin
release; and (v) all times after PI-103 release. The fifth
bicluster of genes highly expressed after PI-103 release
was selected as the PI3K signature for further investiga-
tion (Supplementary Table S3). The first bicluster was ex-
cluded because the relatively high concentration of
LY294002 (50 mm) required to produce maximal inhibi-
tion of PI3K signaling showed slightly reduced viability
relative to untreated TRP2/2 cells at 24 h (93%+2%,
data not shown), was likely to produce off-target
effects, and was less efficient than PI-103 in inhibiting
Akt phosphorylation (Supplementary Fig. S6D). The
second was excluded because we sought to identify
genes that defined activated, not inhibited PI3K signaling.
The thirdwasexcludedbecausegenes expressedonlyafter
24 h of drug release would not contain genes expressed at
earlier time points. The fourth was excluded because
rapamycin-mediated inhibition of mTOR complex 1
(mTORC1) ablated S6, but not Akt phosphorylation
(Supplementary Fig. S6C). Consequently, genes ex-
pressed after rapamcyin release would represent only a
distal PI3K pathway activation signature. In contrast,
PI-103 inhibits PI3K and both mTOR complexes, and it
efficiently reduced phosphorylation of both Akt and S6
in TRP2/2 astrocytes (Supplementary Fig. S6A).
Furthermore, Akt and S6 phosphorylation increased
after PI-103 release, suggesting that both proximal and
distal PI3K pathway signaling resumed in TRP2/2 astro-
cytes released from PI-103 (Supplementary Fig. S6A, D,
E). We identified 518 genes (Supplementary Table S3)
with increased expression after PI-103 release as a PI3K
pathway activation signature and found that these genes
clustered G1/S-defective TRP2/2 astrocytes on the
basis of inhibition or release from each individual drug
(Fig. 6A).
Expression of PI3K signature genes wasnext examined
in 434 human GBM from TCGA30 and was significantly
different across the 4 subtypes (Fig. 6B). Proneural
GBM, in particular, showed significantly higher expres-
sion of PI3K signature genes by ssGSEA (Fig. 6C).
Kras Activation with or without Pten Loss Is Necessary
for G1/S-Defective Astrocyte Tumorigenesis
The complimentary effects of Kras activation and Pten
loss produced highly proliferative, migratory, and inva-
sive G1/S-defective astrocytes in vitro, and their gene ex-
pression profiles correlated with human HGA subtypes.
Next, we used an allograft model system with syngeneic,
immunocompetent hosts to investigatewhether Kras acti-
vation and/or Pten loss was required for tumorigenesis in
vivo. Orthotopic injection of T, TR, TRP+/2, and
TRP2/2 astrocytes produced astrocytomas in 30%,
25%, 64%, and 60% of mice aged up to 1 year or neuro-
logical morbidity (Fig. 7A). Three mice injected with T as-
trocytes developed small foci of LGA that failed to
produce neurological symptoms and progress to HGA
over the course of a year (Supplementary Fig. S7A–D).
Four of 6 astrocytoma-bearing mice injected with TR as-
trocytes developed GBM (Supplementary Fig. 7B and
S7E-H). Thus, although Kras activation was sufficient
for malignant progression, TR GBM developed with
long latency because median survival was 207 days
(Fig. 7C). In contrast, G1/S-defective astrocytes contain-
ing both activated Kras and Pten deletion progressed to
HGA in .97% of mice injected with either TRP+/2 or
Vitucci et al.: Ras and Pten in glioblastoma pathogenesis
1324 NEURO-ONCOLOGY † O C T O B E R 2 0 1 3
Fig. 6. A PI3K signature defined in TRP2/2 astrocytes upon release from PI-103-mediated inhibition of PI3K signaling is enriched in human
proneural GBM. Heatmap of 518 genes with significantly increased expression in TRP2/2 astrocytes after release from PI-103 (A). A box and
whiskers plot of the distribution of mean expression of PI3K signature genes (centroid) (B) and ssGSEA (C) shows that the PI3K signature is
significantly enriched in human proneural (PN), but not neural (N), classical (Cl), and mesenchymal (Mes) GBM from TCGA.
Fig. 7. G1/S-defective astrocytes form astrocytomas after orthotopic injection into syngeneic, immunocompetent mouse brains. Astrocytoma
incidence in terminally aged mice after orthotopic injection of 105 astrocytes (A). The number of mice injected per genotype is indicated. The
fraction of astrocytomas in panel A with histological features of high-grade astrocytomas (HGA) (B). The number of astrocytomas detected
per genotype is indicated. Kaplan–Meier survival analysis of astrocytoma-bearing mice (C). Median survivals were 36, 57, and 207 days for
TRP2/2, TRP+/2, and TR astrocytes, respectively (P , .0001). The incidence of astrocytomas in mice sacrificed between 7 and 28 days after
injection with astrocytes of the indicated genotypes (D).
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TRP2/2 astrocytes, and 89% and 83% of these mice de-
veloped GBM, respectively (Fig. 7B, Supplementary Fig.
S7I-P). Pten deletion also significantly decreased the
latency of G1/S-defective, Kras-activated HGA because
the median survival of mice injected with TRP+/2 and
TRP2/2 astrocytes was 57 and 36 days, respectively
(P ≤ .005) (Fig. 7C). These results show that ablation of
the G1/S checkpoint is sufficient to produce LGA, Kras
activation is required for progression to HGA, and the
combinationof Krasactivation and Pten deletion dramat-
ically increases GBM incidence and reduces survival.
TRP (Supplementary Fig. S7IJ and S7MN) were signif-
icantly more invasive than TR GBM (Supplementary Fig.
S7EF), which largely developed as well-circumscribed
masses. These findings are consistent with the increased
invasion of TRP versus TR astrocytes in vitro (Fig. 3B).
Moreover,TRP GBMcontained cellswith both astrocytic
and oligodendroglial morphology (Supplementary Fig.
S7L and S7P), a finding consistent with their proneural
GBM and murine OPC-like gene expression profiles in
vitro.
To further examine tumor initiation, we injected G1/
S-defective astrocytes with (TR, TRP+/2, and TRP2/2)
and without (TP+/2and TP2/2) activated Kras, sacri-
ficed mice every 7 days for 4 weeks, and evaluated
tumor incidence and histological grade. Similar to T as-
trocytes, TP+/2 and TP2/2 astrocytes infrequently devel-
oped into LGA (Fig. 7D and Supplementary Fig. S8). In
contrast, TRP+/2 and TRP2/2 astrocytes developed
into LGA more efficiently. Mitotically active HGA were
evident in 40% and 10% of mice injected with these
cells, but only one mouse injected with TRP2/2 astro-
cytes developed a GBM within 28 days. These results
suggest that the increased incidence of HGA in mice in-
jected with TRP astrocytes is likely to be attributable to
more efficient tumor initiation.
Discussion
Virtually all human GBM contain RB pathway gene mu-
tations that dysregulate the G1/S cell cycle checkpoint.
Most also contain RTK pathway gene mutations that ac-
tivate RAS/MAPK and PI3K signaling.4 We therefore
used G1/S checkpoint-defective cortical murine astro-
cytes to examine the individual and combined effects of
Ras/MAPK and/or PI3K pathway dysregulation on mul-
tiple cancer-related phenotypes in vitro. Both Kras activa-
tion and Pten loss induced MAPK and PI3K signaling
(Fig. 1). Kras activation, but not Pten loss, increased pro-
liferation and reduced apoptosis of cultured T121
+ astro-
cytes in vitro (Fig. 1D). We have previously shown that
T121 inducesbothproliferationandapoptosis inneonatal,
T121-drivenastrocytomas invivoand thatPten losspoten-
tiates progression by reducing apoptosis.21 These findings
suggest that Kras and Pten signaling perturbations may
affect G1/S-defective astrocyte growth by distinct mech-
anisms depending on their patterns of co-occurrence. The
roleof Pten inp53-dependent apoptosis has long been rec-
ognized, but increasing evidence suggests that nuclear
Pten directly regulates mitosis.31 Decreasing Pten induces
expression of cell cycle and chromosome stability genes
and proliferation of mouse embryonic fibroblasts.32
Moreover, Pten deletion in embryonic mice increases as-
trocyte proliferation in vitro and in vivo.33 Conversely,
exogenous PTEN expression in human glioma cells de-
creases proliferation and lengthens cell cycle transit from
G2/MtoG1.34 Therefore,weconclude that Ptennegative-
ly regulates proliferation in G1/S-defective astrocytes.
Kras activation and/or Pten deletion not only in-
creased MAPK and PI3K pathway signaling and growth
of G1/S-defective astrocytes (Fig. 1) but migration as
well (Fig. 2). However, their effects on invasion were con-
textual (Fig. 3). Kras activation was insufficient for inva-
sion in the absence of Pten deletion, suggesting that
Ras-mediated invasion requires concurrent activation of
PI3K signaling. In contrast, monoallelic Pten deletion
wassufficient to inducemaximal invasiononly in thepres-
ence of activated Kras (Fig. 3B). Biallelic Pten deletion
caused maximal invasion in both the presence and the
absence of activated Kras (Fig. 3B), and Pten restoration
significantly reduced invasion (Fig. 4E). However, Pten
restoration did not completely abrogate migration and in-
vasion, likely because of ,100% transfection efficiency.
Thus, a subpopulation of cells in these assays lacked
Pten expression and retained their migratory and invasive
properties. These results indicate that Pten is a primary
regulator of G1/S-defective astrocyte invasion and that
the invasion-related effects of biallelic, but not monoal-
lelic, Pten deletion are independent of activated Kras.
Established human cell lines, such as U87MG, have
previously been used in genetic gain and loss of function
studies to investigate the molecular mechanisms of
GBM migration and invasion in vitro.35 PTEN restora-
tion has been shown to inhibit proliferation, migration,
and invasion of human PTEN-null U87MG astrocytoma
cells in vitro.36 PDGF-induced migration of U87MG cells
has also been shown to be PI3K, but not ERK, depen-
dent,37 and farnesyltransferase-mediated inhibition of
Ras reduced U87MG migration in a PI3K-dependent
manner.38 However, established cell lines harbor wide-
spread genomic alterations that frequently differ from
their original tumor.39,40 Therefore, panels of established
cell lines, each with distinct genomic landscapes, are typ-
ically used to rule out cell line-specific effects. Our use of
an allelic series of genetically defined astrocytes contain-
ing defined core signaling pathway mutations removes
ambiguity associated with established human cell lines
and provides a unique opportunity to clarify genotype-
phenotype relationships in GBM pathogenesis. Our
data therefore confirm and extend studies that used estab-
lished human astrocytoma cell lines to demonstrate that
PTEN is a critical regulator of migration and invasion
and that RAS-dependent invasion requires PI3K/PTEN
signaling.
In addition to their effects on growth, migration, and
invasion, mutations that activate Ras/MAPK and PI3K
signaling produced 3 distinct gene expression clusters
that correlated with mutation and pathway activation
status (Fig. 5). Activation of both pathways in cultured
TRPastrocytes definedatranscriptomal class (Class3) en-
riched for migratory, invasive, and stem-like signatures.
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TRP astrocytes also showed high expression of human
proneural GBM and murine OPC signatures. These find-
ings are consistent with previous reports demonstrating
similarity between proneural GBM and OPC.26,28
Additionally, an activated PI3K pathway signature
defined in TRP astrocytes released from PI3K pathway in-
hibition was enriched in human proneural GBM (Fig. 6).
The above data suggest that TRP astrocytes would
form invasive astrocytomas in vivo. We used a novel
orthotopic allograft model with syngeneic, immunocom-
petent hosts to show that G1/S-defective astrocytes with
activated Kras and/or Pten deletion formed astrocytomas
with penetrance that correlated with mutational status
(Fig. 7). Specifically, both Kras activation and Pten dele-
tion were required for high-penetrance tumorigenesis
and efficient progression to HGA. Similar results were ob-
tained in conditional, inducible GEM, in which these
genetic mutations are targeted specifically to adult
GFAP+ cortical astrocytes.20 These findings suggest
that cortical astrocytes may serve as a potential astrocyto-
ma cell of origin, particularly in tumors with G1/S check-
point dysfunction, activated Kras, and Pten deletion.
TRP allografts diffusely invaded normal brain and
formed histopathological hallmarks of human astrocyto-
mas, including perineuronal and perivascular sattelitosis,
migration and invasion along white matter tracks, elevat-
ed mitoses, microvascular proliferation, and necrosis
(Supplementary Fig. S7). These histopathological fea-
tures contrast significantlywithhuman U87MG GBM xe-
nografts, which are poorly invasive in vivo,23 and suggest
that this model system will be useful for further dissection
of the genetics of astrocytoma migration and invasion.
We conclude that the syngeneic, orthotopic TRP allograft
model represents a significant improvement over tradi-
tional xenografts models that use established human cell
lines and immunodeficient mice.
Consistent with the expression profiles of TRP astro-
cytes in vitro (Fig. 5) and the presence of oligodendroglial
differentiation in vivo (Supplementary Fig. S7), TRP
allografts also showed enriched expression of human pro-
neuralGBMandmurineOPCsignaturegenes (manuscript
in preparation). The Rb family of G1/S cell cycle proteins,
Nf1, a negative regulator of Ras/MAPK signaling, and
Ptenhaveeachbeen showntoregulateneural stemcell self-
renewal and fate.41–43 These results suggest that com-
bineddysregulationofRb,Ras, andPten reverts astrocytes
to a progenitor-like state of gene expression.
The use of gene expression profiling to characterize the
molecular heterogeneity and improve diagnostic classifi-
cation of specific types of brain tumors has recently
brought significant attention to defining their cellular
origins. We used GEM models to show that the molecular
heterogeneity of medulloblastoma, the most common
primary brain tumor in children, has a cellular and
genetic basis.44 Similar to HGA, multiple genomic sub-
types of human medulloblastoma with distinct mutations
exist.45 Furthermore, GEM models have shown that dif-
ferent initiating oncogenic mutations in specific cells of
origin in the developing mouse cerebellum lead to distinct
genomic subtypes of medulloblastoma that mimic their
human counterparts.
Gene expression profiling of human HGA has suggest-
ed that the subtypes may have distinct cellular
origins.26,46 GEM modeling studies have identified
neural stem cells47 and OPC46 as potential candidate as-
trocytoma cells of origin.48 PDGF-driven murine GBM
derived from adult Pten-null OPC were shown to have
transcriptomes similar to human proneural GBM.46
Here, we identified proneural and OPC-like expression
specifically in G1/S-defective neonatal murine astrocytes
with activated Kras and Pten deletion (Fig. 5D). The pres-
ence of human proneural GBM and OPC-like expression
profiles in both PDGF-driven GBM and TRP astrocyte-
derived GBM allografts suggests that molecularly
similarGBMcanarise fromat least2distinctgeneticmech-
anisms and cellular origins. We speculate that multiple cell
types can lead to GBM and that different cells are uniquely
susceptible, within defined developmental windows, to the
transformingeffects ofparticularcombinationsof core sig-
naling pathway mutations. These combined factors deter-
mine the human astrocytoma transcriptomal subtype.
Such a unifying hypothesis would explain the associations
between transcriptomal subtype, mutational landscape,
signaling pathway alterations, and neural signatures in
human GBM.26,27,49
The in vitro experiments described above show that
growth, motility, and invasive phenotypes are differen-
tially affected by specific genetic alterations in the RTK
core GBM-signaling pathway. These alterations may ulti-
mately dictate targeted GBM therapy. As such, we have
used MAPK- and PI3K-targeted drugs to reduce in vitro
migration, invasion, and signaling in TRP astrocytes tran-
scriptionally similar to human proneural GBM (Fig. 2D,
3C, Supplementary Fig. S6). Release of TRP astrocytes
frompharmacologicalPI3Kpathwayinhibition identified
a PI3K signature significantly enriched in human proneu-
ral GBM (Fig. 6). The findings that TRP astrocytes con-
tained a PI3K activation signature enriched in proneural
human GBM and produced proneural-like HGA allo-
grafts after injection into syngeneic, immunocompetent
brains suggest that proneural GBM may be uniquely sen-
sitive to combination therapies targeting both RAS/
MAPK and PI3K. The TRP allograft model of human pro-
neural GBM will not only facilitate delineation of the mo-
lecular requirements for tumorigenesis and cellular
origins of astrocytomas but will also be useful for preclin-
ical testing of drug combinations and elucidating poten-
tial mechanisms of resistance. Moreover, the use of
syngeneic, immunocompetent hostswill facilitatepreclin-
ical testing of immunotherapies.
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